{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:08:28Z","timestamp":1761887308521,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T00:00:00Z","timestamp":1645833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.nrleng.2021.05.006","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:31:19Z","timestamp":1646382679000},"page":"231-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypercholesterolaemia treatment in a patient with family hypercholesterolaemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors"],"prefix":"10.1016","volume":"37","author":[{"given":"P.","family":"Luque Linero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Castilla-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rojas Marcos Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Rico Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2021.05.006_bib0005","first-page":"43","article-title":"Update review about metabolic myopathies","volume":"10","author":"Finsterer","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0010","first-page":"112","article-title":"Insuficiencia renal aguda debido a deficiencia de carnitina palmitoil transferasa","volume":"28","author":"Hern\u00e1ndez Hern\u00e1ndez","year":"2008","journal-title":"Nefrologia"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21873\/invivo.12232","article-title":"PCSK9 antibody-based treatment strategies for patients with statin intolerance","volume":"35","author":"Voutyritsa","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0020","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de posicionamiento terap\u00e9utico PT_evolocumab\/V1\/03032016. De 03-03-2016 [accessed 1 Abr 2021]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-evolocumab-repatha.pdf."},{"issue":"Suppl. 8A","key":"10.1016\/j.nrleng.2021.05.006_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/jcm9010022","article-title":"Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components","volume":"9","author":"Turner","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factor associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nrleng.2021.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc Res"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580822000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:33:21Z","timestamp":1761881601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580822000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2173580822000219"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.05.006","relation":{},"ISSN":["2173-5808"],"issn-type":[{"type":"print","value":"2173-5808"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypercholesterolaemia treatment in a patient with family hypercholesterolaemia and myopathy due to carnitine palmitoyltransferase II deficiency with PCSK9 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2021.05.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}